Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia

doi:10.1017/CBO9780511543630.012

10 - Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia

Published online by Cambridge University Press: 07 December 2009

D. Cyril D'souza ,

Hyun-Sang Cho ,

Edward B. Perry and

John H. Krystal

Edited by

David Castle and

Robin Murray

Show author details

D. Cyril D'souza: Affiliation:
Yale University School of Medicine
Hyun-Sang Cho: Affiliation:
Yale University School of Medicine
Edward B. Perry: Affiliation:
Yale University School of Medicine
John H. Krystal: Affiliation:
Yale University School of Medicine
David Castle: Affiliation:
Mental Health Research Institute, Melbourne
Robin Murray: Affiliation:
Institute of Psychiatry, London

Book contents

Get access

Summary

Hypotheses relating to the association between cannabis and psychosis may be divided into two groups. The exogenous hypothesis, which has received far greater attention, suggests that the consumption of cannabinoid compounds produces psychotic disorders by mechanisms that are extrinsic to the pathophysiology of naturally occurring psychoses. As discussed elsewhere in this book, converging evidence from epidemiological, genetic, neurochemical, pharmacological and postmortem studies have provided support for an association between ‘cannabis and madness’ (see Chapters 3, 6, 8 and 9). These data also suggest a second, relatively nascent endogenous hypothesis, according to which cannabinoid (CB1) receptor dysfunction may contribute to the pathophysiology of psychosis and/or schizophrenia, and further, that the putative CB1 receptor dysfunction may be unrelated to the consumption of cannabinoid compounds.

This chapter addresses the exogenous hypothesis of cannabis consumption and psychosis. First, we review studies from a number of sources, supporting an association between cannabis consumption and the manifestation of psychotic symptoms in humans (the interested reader is referred to Chapters 3 and 5 for a more detailed exposition). We then detail a recent pharmacological study that assessed the effects of exposure to the principal psychoactive constituent of cannabis, Δ9- tetrahydrocannabinol (Δ9-THC) in patients with schizophrenia and normal controls. We conclude by suggesting possible mechanisms by which cannabis may induce psychosis and articulate the implications of these findings for a potential endocannabinoid contribution to the pathophysiology of schizophrenia.

Type: Chapter
Information: Marijuana and Madness
Psychiatry and Neurobiology
, pp. 142 - 165

DOI: https://doi.org/10.1017/CBO9780511543630.012 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association

Ames, F. (1958). A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in model psychoses. J. Mental Sci., 104, 972–999CrossRef Google Scholar PubMed

Anderson, J. J., Kask, A. M. and Chase, T. N. (1996). Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur. J. Pharmacol., 295, 163–168CrossRef Google Scholar PubMed

Ashton, C. H. (2001). Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry, 179, 270–271Google Scholar

Auclair, N., Otani, S., Soubrie, P. and Crepel, F. (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol., 83, 3287–3293CrossRef Google Scholar PubMed

Azorlosa, J. L., Heishman, S. J., Stitzer, M. L. and Mahaffey, J. M. (1992). Marijuana smoking: effect of varying delta 9-tetrahydrocannabinolcontent and number of puffs. J. Pharmacol. Exp. Ther., 261, 114–122Google Scholar PubMed

Baker, P. B., Taylor, B. J. and Gough, T. A. (1981). The tetrahydrocannabinol and tetrahydrocannabinolic acid content of cannabis products. J. Pharm. Pharmacol., 33, 369–372CrossRef Google Scholar PubMed

Banerjee, S. P., Snyder, S. H. and Mechoulam, R. (1975). Cannabinoids: influence on neurotransmitter uptake in rat brain. J. Pharmacol. Exp. Ther., 194, 74–81Google Scholar PubMed

Berk, M., Brook, S. and Trandafir, A. I. (1998). A comparison of olanzapine with haloperidol in cannabis-induced psychotic: a double-blind randomized controlled trial. Int. Clin. Psychopharmacol., 14, 177–180Google Scholar

Bloom, A. S. (1982). Effect of delta-9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. J. Pharmacol. Exp. Ther., 221, 97–103Google Scholar PubMed

Bonnin, A., de-Miguel, R., Castro, J. G., Raos, J. A. and Fernadez-Ruiz, J. J. (1996). Effects of perinatal exposure to delta-9-THC on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J. Mol. Neurosci., 7, 291–308CrossRef Google Scholar PubMed

Bornheim, L. M. and Grillo, M. P. (1998). Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem. Res. Toxicol., 11, 1209–1216CrossRef Google Scholar PubMed

Bremner, J. D., Krystal, J. H., Putnam, F. W.et al. (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J. Trauma Stress 11, 125–136CrossRef Google Scholar

Chait, L. D. and Perry, J. L. (1992). Factors influencing self-administration of, and subjective response to, placebo marijuana, Behav. Pharmacol., 3, 545–552Google Scholar PubMed

Chen, J., Paredes, W., Lowinson, J. H. and Gardner, E. L. (1990). Delta-9-tetrahydrocannabinol enhances presynaptic dopamine efflux in the medial prefrontal cortex. Eur. J. Pharmacol., 190, 259–262Google Scholar PubMed

Chen, J., Paredes, W., Lowinson, J. H. and Gardner, E. L. (1991). Strain specific facilitation of dopamine efflux by delta-9-tetrahydrocannabinol in the nucleus accumbens of the rats: an in vivo microdialysis study. Neurosci. Lett., 129, 136–140CrossRef Google Scholar PubMed

Chen, J., Marmur, R., Pulles, A., Paredes, W. and Gardner, E. L. (1993). Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res., 621, 65–70CrossRef Google Scholar

Collins, D. R., Pertwee, R. G. and Davies, S. N. (1994). The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur. J. Pharmacol., 259, R7–R8CrossRef Google Scholar PubMed

Collins, D. R., Pertwee, R. G. and Davies, S. N. (1995). Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol., 115, 869–870CrossRef Google Scholar PubMed

Diana, M., Melis, M. and Gessa, G. L. (1998). Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids, Eur. J. Neurosci., 10, 2825–2830CrossRef Google Scholar PubMed

Dolan, R. J., Fletcher, P., Frith, C. D.et al. (1995). Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature, 378, 180–182CrossRef Google Scholar

Ferrari, F., Ottani, A. and Giuliani, D. (1999). Influence of the cannabinoid agonist HU 210 on cocaine and CQP 201–403-induced behavioural effects in rat. Life Sci., 65, 823–831CrossRef Google Scholar PubMed

French, E. D., Dillon, K. and Wu, X. (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport, 8, 649–652CrossRef Google Scholar PubMed

Gellman, R. L. and Aghajanian, G. K. (1993). Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res., 600, 63–73CrossRef Google Scholar PubMed

Gessa, G. L., Melis, M., Muntoni, A. L. and Diana, M. (1998). Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol., 341, 39–44CrossRef Google Scholar PubMed

Gioanni, Y., Thierry, A. M., Glowinski, J. and Tassin, J. P. (1998). Alpha1-adrenergic, D1, and D2 receptors interactions in the prefrontal cortex: implication for modality of action of different types of neuroleptics. Synapse, 30, 362–3703.0.CO;2-W>CrossRef Google Scholar

Giuffrida, A., Parsons, L. H., Kerr, T. M.et al. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci., 2, 358–363CrossRef Google Scholar PubMed

Goldman-Rakic, P. S. (1987). The circuitry of primate prefrontal cortex and the regulation of behavior by representational memory. In Handbook of Physiology: The Nervous System, ed. V. M. Mountcastle, pp. 373–417. Bethesda, MD: American Physiological Society

Gorriti, M. A., Rodriguez de Fonseca, F., Navarro, M. and Palomo, T. (1999) Chronic (–)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur. J. Pharmacol., 365, 33–42CrossRef Google Scholar

Grobin, A. C. and Deutch, A. Y. (1998). Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex. J. Pharmacol. Exp. Ther., 285, 350–357Google Scholar PubMed

Hájos, N., Katona, I., Naiem, S. S.et al. (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci., 12, 3239–3249CrossRef Google Scholar PubMed

Hampson, A. J., Grimaldi, M., Lolic, M.et al. (2000). Neuroprotective antioxidants from marijuana, Ann. NY Acad. Sci., 899, 274–282CrossRef Google Scholar PubMed

Herkenham, M., Lynn, A. B., Little, M. D.et al. (1990). Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci., 87, 1932–1936CrossRef Google Scholar PubMed

Herkenham, M., Lynn, A. B., Johnson, M. R.et al. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 11, 563–583CrossRef Google Scholar PubMed

Hernandez, M. L., Garcia-Gil, L., Berrendro, F., Ramos, J. A. and Fernandez-Ruiz, J. J. (1997). δ-9-tetrahydrocannabinol increases the activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. J. Mol. Neurosci., 8, 83–91CrossRef Google Scholar PubMed

Hershkowitz, M., Goldman, R. and Raz, A. (1977). Effect of cannabinoids on neurotransmitter uptake. ATPase activity and morphology of mouse brain synaptosomes. Biochem. Pharmacol., 26, 1327–1331CrossRef Google Scholar

Hoffman, A. F. and Lupica, C. R. (2000). Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci., 20, 2470–2479CrossRef Google Scholar PubMed

Isbell, H., Gorodetsky, C. W., Jasinski, D. R.et al. (1967). Effects of delta-9-transhydrocannabinol in man. Psychopharmacologia, 11, 184–188CrossRef Google Scholar PubMed

Johnson, K. M., Ho, B. T. and Dewey, W. L. (1976). Effects of delta9-tetrahydrocannabinol on neurotransmitter accumulation and release mechanisms in rat forebrain synaptosomes. Life Sci., 19, 347–356CrossRef Google Scholar PubMed

Jones, R. T. (1971). Tetrahydrocannabinol and the marijuana-induced social “high,” or the effects of the mind on marijuana. Ann. NY Acad. Sci., 191, 155–165CrossRef Google Scholar

Kay, S. R. and Opler, L. A. (1986). Positive and Negative Symptoms Scale (PANSS) Rating Manual. Bronx, New York: Albert Einstein College of Medicine, Department of Psychiatry

Leweke, F. M., Schneider, U., Thies, M., Munte, T. F. and Emrich, H. M. (1999). Effects of synthetic delta-9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacologia, 142, 230–235CrossRef Google Scholar PubMed

Maitre, L., Staehelin, M. and Bein, H. J. (1970). Effect of an extract of cannabis and of some cannabinols on catecholamine metabolism in rat brain and heart. Agents Actions, 1, 136–143CrossRef Google Scholar PubMed

Marsicano, G. and Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11, 4213–4225CrossRef Google Scholar PubMed

Masserano, J. M., Karoum, F. and Wyatt, R. J. (1999). SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav. Pharmacol., 10, 429–432CrossRef Google Scholar PubMed

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564CrossRef Google Scholar PubMed

Mayor's Committee On Marijuana (1944). The Marijuana Problem in the City of New York. Lancaster, PA: Jacques Catell Press

McPartland, J. M. and Russo, E. B. (2001). Cannabis and cannabis extracts: greater than the sum of their parts?J. Cannabis Ther., 1, 103–132CrossRef Google Scholar

Mechoulam, R. and Ben-Shabat, S. (1999). From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nature Prod. Rep., 16, 131–143CrossRef Google Scholar PubMed

Meschler, J. P., Conley, T. J. and Howlett, A. C. (2000). Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol. Biochem. Behav., 67, 567–573CrossRef Google Scholar PubMed

Miller, L. L. (1984). Marijuana: acute effects on human memory. In The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects, ed. S. Agurell, W. L. Dewey and R. E. Willette, pp. 21–46. New York, NY: Academic PressCrossRef

Miller, L. and Branconnier, R. J. (1983). Cannabis: effects on memory and the cholinergic limbic system. Psychol. Bull., 99, 441–456CrossRef Google Scholar

Misner, D. L. and Sullivan, J. M. (1999). Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J. Neurosci., 19, 6795–6805CrossRef Google Scholar PubMed

Miyamoto, A., Yamamoto, T., Ohno, M.et al. (1996). Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res., 710, 234–240CrossRef Google Scholar PubMed

Nicoll, R. A. and Malenka, R. C. (1995). Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature, 377, 115–118CrossRef Google Scholar PubMed

Nowicky, A. V., Teyler, T. J. and Vardaris, R. M. (1987). The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Res. Bull., 19, 663–672CrossRef Google Scholar

Patel, S. and Hillard, C. J. (2003). Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther., 297, 629–637Google Scholar

Perlstein, W. M., Carter, C. S., Noll, D. C. and Cohen, J. D. (2001). Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry, 158, 1105–1113CrossRef Google Scholar

Pettit, D. A., Harrison, M. P., Olson, J. M., Spencer, R. F. and Cabral, G. A. (1998). Immuno-histochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res., 51, 391–4023.0.CO;2-A>CrossRef Google Scholar

Piomelli, D., Giuffrida, A., Calignano, A. and Rodriguez de Fonseca, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218–224CrossRef Google Scholar PubMed

Pirot, S., Godbout, R., Mantz, J.et al. (1992). Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience, 49, 857–865CrossRef Google Scholar PubMed

Pistis, M., Porcu, G., Melis, M., Diana, M. and Gessa, G. L. (2001). Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur. J. Neurosci., 14, 96–102CrossRef Google Scholar PubMed

Poddar, M. K. and Dewey, W. L. (1980). Effects of cannabinoids of catecholamine uptake and release in hypothalmic and striatal synaptosomes. J. Pharmacol. Exp. Ther., 214, 63–67Google Scholar

Rodriguez de Fonseca, F., Del Arco, I., Martin-Calderon, J. L., Gorriti, M. A. and Navarro, M. (1998). Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol. Dis., 5, 483–501CrossRef Google Scholar PubMed

Sullivan, J. M. (1999). Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. J. Neurophysiol., 82, 1286–1294CrossRef Google Scholar PubMed

Szabo, B., Siemes, S. and Wallmichrath, I. (2002). Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci., 5, 2057–2061CrossRef Google Scholar

Tanda, G., Pontieri, F. E. and Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science, 276, 2048–2050CrossRef Google Scholar PubMed

Terranova, J. P., Michaud, J. C., Fur, G. and Soubrie, P. (1995). Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212–2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedebergs Arch. Pharmakol., 352, 576–579CrossRef Google Scholar PubMed

Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K. and Walker, J. M. (1998). Immuno-histochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83, 393–411CrossRef Google Scholar

Tsou, K., Mackie, K., Sanudo-Pena, M. C. and Walker, J. M. (1999). Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience, 93, 969–975CrossRef Google Scholar PubMed

Wilson, R. I. and Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature, 410, 588–592CrossRef Google Scholar PubMed

Wilson, R. I. and Nicoll, R. A. (2002). Endocannabinoid signalling in the brain. Science, 296, 678–682CrossRef Google Scholar

Wu, X. and French, E. D. (2000). Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacologia, 39, 391–398CrossRef Google Scholar

Zuardi, A. W., Shirakawa, I., Finkelfarb, E. and Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmalogia, 76, 245–250CrossRef Google Scholar PubMed

Zuardi, A. W., Morais, S. L., Guimaraes, F. S. and Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. J. Clin. Psychiatry, 56, 485–486Google Scholar PubMed